Cargando…

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis

Background: Dolutegravir-containing maintenance therapy is a promising simplification strategy for virologically suppressed HIV-infected individuals. However, most of the available data to inform this strategy come from small, uncontrolled studies. We estimated the proportion of HIV-infected patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wandeler, Gilles, Buzzi, Marta, Anderegg, Nanina, Sculier, Delphine, Béguelin, Charles, Egger, Matthias, Calmy, Alexandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134332/ https://www.ncbi.nlm.nih.gov/pubmed/30271590 http://dx.doi.org/10.12688/f1000research.15995.2

Ejemplares similares

Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial
por: Sculier, Delphine, et al.
Publicado: (2020)

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018)

Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible
por: Pena, M J, et al.
Publicado: (2018)

HIV suppression was maintained during the COVID-19 pandemic in Malawi: a program-level cohort study
por: Kalua, Thokozani, et al.
Publicado: (2022)

Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV
por: Sangaré, Mohamed N’dongo, et al.
Publicado: (2020)

Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation
por: Panayidou, Klea, et al.
Publicado: (2018)

Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study
por: Hauser, Anthony, et al.
Publicado: (2020)

Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literature
por: Sculier, Delphine, et al.
Publicado: (2014)

Survival among people hospitalized with COVID-19 in Switzerland: a nationwide population-based analysis
por: Anderegg, Nanina, et al.
Publicado: (2022)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
por: Olearo, Flaminia, et al.
Publicado: (2019)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
por: Olearo, Flaminia, et al.
Publicado: (2019)

Lipohypertrophy and metabolic disorders in HIV patients on antiretroviral therapy: a systematic multidisciplinary clinical approach
por: Sculier, Delphine, et al.
Publicado: (2014)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study
por: Sculier, Delphine, et al.
Publicado: (2017)

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2022)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023)

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
por: Borghetti, Alberto, et al.
Publicado: (2021)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

549. Weight and BMI Changes in HIV-Infected Virologically Suppressed Adults after Switching to an Elvitegravir- or Dolutegravir-Containing Regimen
por: Gibson, Amanda, et al.
Publicado: (2018)

Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients
por: Scherrer, Alexandra U., et al.
Publicado: (2012)

Hepatitis C in HIV-infected individuals: a systematic review and meta-analysis of estimated prevalence in Africa
por: Azevedo, Tiago Castro Lopes, et al.
Publicado: (2016)

Retention in Care of HIV-Infected Children from HIV Test to Start of Antiretroviral Therapy: Systematic Review
por: Mugglin, Catrina, et al.
Publicado: (2013)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

Simplified Assessment of Antiretroviral Adherence and Prediction of Virological Efficacy in HIV-Infected Patients in Cambodia
por: Segeral, Olivier, et al.
Publicado: (2010)

Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study: A Cross-Sectional Study
por: Mauri, Fabio, et al.
Publicado: (2022)

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
por: Bhatt, Nilesh B., et al.
Publicado: (2015)

Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study
por: Salazar-Vizcaya, Luisa, et al.
Publicado: (2018)

Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics
por: Fokam, Joseph, et al.
Publicado: (2023)

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
por: Bollen, Pauline D J, et al.
Publicado: (2020)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor–Based Antiretroviral Treatment
por: Pyngottu, Ashima, et al.
Publicado: (2020)

The role of dolutegravir in the management of HIV infection
por: Miller, Misty M, et al.
Publicado: (2015)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons
por: Bihl, Florian, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k8o9q9lngru1ckltppd212o1am